ALSO NOTED: Pfizer to buy CovX; Florida commits $94M to Max Planck; Affymetrix buys USB; HGS touts animal trial results for ant

> Aggressively looking to expand its role in biologics, Pfizer has struck a deal to buy CovX. No figures were given. Report

> Florida's governor has committed $94 million to bring the Max Planck Society to Palm Beach County, making it a neighbor of Scripps Florida. Report

> Affymetrix is buying USB, which makes molecular biology and biochemical reagent products, for $75 million. Release

> The FDA has approved Forest Laboratories' hypertension drug Bystolic, which it plans to launch next month. Release

> Human Genome Sciences says that animal studies of a new anthrax therapy have demonstrated marked results. Release

> Insmed has received the FDA's Orphan Drug Designation for IPLEX, a treatment of myotonic muscular dystrophy. Release

> Elixir set the terms for its IPO at $14 to $16 a share. Report

> Belgium's Ablynx is touting the results of a Phase I trial of its ALX-0081 nanobody for thrombosis. Release

> Biomarin announced today that it has re-acquired the Canadian rights for tetrahydrobiopterin, including Kuvan, from Merck Serono, The FDA has granted marketing approval for BioMarin Pharmaceutical's Kuvan tablets, a specific drug therapy for the treatment of phenylketonuria. Release

> Medarex will receive an undisclosed milestone payment from Amgen for advancing an antibody into human clinical trials. Release

> Merck and Schering-Plough have responded to public outcry over their plans to re-jig a study of Vytorin, a joint product that combines Merck's Zocor and Schering-Plough's Zetia. Report

> The Internet is buzzing about a Wall Street Journal op-ed piece in which ex-FDA deputy commissioner Scott Gottlieb (photo) championed the sort of off-label promotions that make regulators crazy. Report

> Counterfeit drugmakers have found some unlikely allies: free trade zones. Report

And Finally… A new DNA sequencing technique could dramatically lower the cost to read human genomes. Article

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.